The global market for Familial Amyloid Polyneuropathy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.

Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.

This report aims to provide a comprehensive presentation of the global market for Familial Amyloid Polyneuropathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Familial Amyloid Polyneuropathy.

The Familial Amyloid Polyneuropathy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Familial Amyloid Polyneuropathy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Familial Amyloid Polyneuropathy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Familial Amyloid Polyneuropathy Market Report

Report Metric	Details
Report Name	Familial Amyloid Polyneuropathy Market
Segment by Type	FAP-I FAP-II FAP-III FAP-IV
Segment by Application	Hospitals and Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Familial Amyloid Polyneuropathy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Familial Amyloid Polyneuropathy Market report?

Ans: The main players in the Familial Amyloid Polyneuropathy Market are Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics

What are the Application segmentation covered in the Familial Amyloid Polyneuropathy Market report?

Ans: The Applications covered in the Familial Amyloid Polyneuropathy Market report are Hospitals and Clinics, Others

What are the Type segmentation covered in the Familial Amyloid Polyneuropathy Market report?

Ans: The Types covered in the Familial Amyloid Polyneuropathy Market report are FAP-I, FAP-II, FAP-III, FAP-IV

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 FAP-I

1.2.3 FAP-II

1.2.4 FAP-III

1.2.5 FAP-IV

1.3 Market by Application

1.3.1 Global Familial Amyloid Polyneuropathy Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals and Clinics

1.3.3 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Familial Amyloid Polyneuropathy Market Perspective (2020-2031)

2.2 Global Familial Amyloid Polyneuropathy Growth Trends by Region

2.2.1 Global Familial Amyloid Polyneuropathy Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Familial Amyloid Polyneuropathy Historic Market Size by Region (2020-2025)

2.2.3 Familial Amyloid Polyneuropathy Forecasted Market Size by Region (2026-2031)

2.3 Familial Amyloid Polyneuropathy Market Dynamics

2.3.1 Familial Amyloid Polyneuropathy Industry Trends

2.3.2 Familial Amyloid Polyneuropathy Market Drivers

2.3.3 Familial Amyloid Polyneuropathy Market Challenges

2.3.4 Familial Amyloid Polyneuropathy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue

3.1.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue (2020-2025)

3.1.2 Global Familial Amyloid Polyneuropathy Revenue Market Share by Players (2020-2025)

3.2 Global Familial Amyloid Polyneuropathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Familial Amyloid Polyneuropathy Revenue

3.4 Global Familial Amyloid Polyneuropathy Market Concentration Ratio

3.4.1 Global Familial Amyloid Polyneuropathy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Revenue in 2024

3.5 Global Key Players of Familial Amyloid Polyneuropathy Head office and Area Served

3.6 Global Key Players of Familial Amyloid Polyneuropathy, Product and Application

3.7 Global Key Players of Familial Amyloid Polyneuropathy, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Familial Amyloid Polyneuropathy Breakdown Data by Type

4.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Type (2020-2025)

4.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2026-2031)

5 Familial Amyloid Polyneuropathy Breakdown Data by Application

5.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Application (2020-2025)

5.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Familial Amyloid Polyneuropathy Market Size (2020-2031)

6.2 North America Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Familial Amyloid Polyneuropathy Market Size by Country (2020-2025)

6.4 North America Familial Amyloid Polyneuropathy Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Familial Amyloid Polyneuropathy Market Size (2020-2031)

7.2 Europe Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Familial Amyloid Polyneuropathy Market Size by Country (2020-2025)

7.4 Europe Familial Amyloid Polyneuropathy Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Familial Amyloid Polyneuropathy Market Size (2020-2031)

8.2 Asia-Pacific Familial Amyloid Polyneuropathy Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2020-2025)

8.4 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Familial Amyloid Polyneuropathy Market Size (2020-2031)

9.2 Latin America Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2020-2025)

9.4 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Familial Amyloid Polyneuropathy Market Size (2020-2031)

10.2 Middle East & Africa Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2020-2025)

10.4 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Familial Amyloid Polyneuropathy Introduction

11.1.4 Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 GSK

11.2.1 GSK Company Details

11.2.2 GSK Business Overview

11.2.3 GSK Familial Amyloid Polyneuropathy Introduction

11.2.4 GSK Revenue in Familial Amyloid Polyneuropathy Business (2020-2025)

11.2.5 GSK Recent Development

11.3 Ionis

11.3.1 Ionis Company Details

11.3.2 Ionis Business Overview

11.3.3 Ionis Familial Amyloid Polyneuropathy Introduction

11.3.4 Ionis Revenue in Familial Amyloid Polyneuropathy Business (2020-2025)

11.3.5 Ionis Recent Development

11.4 Alnylam

11.4.1 Alnylam Company Details

11.4.2 Alnylam Business Overview

11.4.3 Alnylam Familial Amyloid Polyneuropathy Introduction

11.4.4 Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2020-2025)

11.4.5 Alnylam Recent Development

11.5 Corino Therapeutics

11.5.1 Corino Therapeutics Company Details

11.5.2 Corino Therapeutics Business Overview

11.5.3 Corino Therapeutics Familial Amyloid Polyneuropathy Introduction

11.5.4 Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2020-2025)

11.5.5 Corino Therapeutics Recent Development

11.6 Proclara Bioscience

11.6.1 Proclara Bioscience Company Details

11.6.2 Proclara Bioscience Business Overview

11.6.3 Proclara Bioscience Familial Amyloid Polyneuropathy Introduction

11.6.4 Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2020-2025)

11.6.5 Proclara Bioscience Recent Development

11.7 Arcturus Therapeutics

11.7.1 Arcturus Therapeutics Company Details

11.7.2 Arcturus Therapeutics Business Overview

11.7.3 Arcturus Therapeutics Familial Amyloid Polyneuropathy Introduction

11.7.4 Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2020-2025)

11.7.5 Arcturus Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Arcturus Therapeutics

List of Tables

Table 1. Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of FAP-I

Table 3. Key Players of FAP-II

Table 4. Key Players of FAP-III

Table 5. Key Players of FAP-IV

Table 6. Global Familial Amyloid Polyneuropathy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Familial Amyloid Polyneuropathy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Familial Amyloid Polyneuropathy Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Familial Amyloid Polyneuropathy Market Share by Region (2020-2025)

Table 10. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Familial Amyloid Polyneuropathy Market Share by Region (2026-2031)

Table 12. Familial Amyloid Polyneuropathy Market Trends

Table 13. Familial Amyloid Polyneuropathy Market Drivers

Table 14. Familial Amyloid Polyneuropathy Market Challenges

Table 15. Familial Amyloid Polyneuropathy Market Restraints

Table 16. Global Familial Amyloid Polyneuropathy Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Familial Amyloid Polyneuropathy Market Share by Players (2020-2025)

Table 18. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2024)

Table 19. Ranking of Global Top Familial Amyloid Polyneuropathy Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Familial Amyloid Polyneuropathy, Headquarters and Area Served

Table 22. Global Key Players of Familial Amyloid Polyneuropathy, Product and Application

Table 23. Global Key Players of Familial Amyloid Polyneuropathy, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Familial Amyloid Polyneuropathy Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type (2020-2025)

Table 27. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type (2026-2031)

Table 29. Global Familial Amyloid Polyneuropathy Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Familial Amyloid Polyneuropathy Revenue Market Share by Application (2020-2025)

Table 31. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Familial Amyloid Polyneuropathy Revenue Market Share by Application (2026-2031)

Table 33. North America Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Familial Amyloid Polyneuropathy Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Familial Amyloid Polyneuropathy Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Familial Amyloid Polyneuropathy Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Familial Amyloid Polyneuropathy Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Familial Amyloid Polyneuropathy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Familial Amyloid Polyneuropathy Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Familial Amyloid Polyneuropathy Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2026-2031) & (US$ Million)

Table 48. Pfizer Company Details

Table 49. Pfizer Business Overview

Table 50. Pfizer Familial Amyloid Polyneuropathy Product

Table 51. Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2020-2025) & (US$ Million)

Table 52. Pfizer Recent Development

Table 53. GSK Company Details

Table 54. GSK Business Overview

Table 55. GSK Familial Amyloid Polyneuropathy Product

Table 56. GSK Revenue in Familial Amyloid Polyneuropathy Business (2020-2025) & (US$ Million)

Table 57. GSK Recent Development

Table 58. Ionis Company Details

Table 59. Ionis Business Overview

Table 60. Ionis Familial Amyloid Polyneuropathy Product

Table 61. Ionis Revenue in Familial Amyloid Polyneuropathy Business (2020-2025) & (US$ Million)

Table 62. Ionis Recent Development

Table 63. Alnylam Company Details

Table 64. Alnylam Business Overview

Table 65. Alnylam Familial Amyloid Polyneuropathy Product

Table 66. Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2020-2025) & (US$ Million)

Table 67. Alnylam Recent Development

Table 68. Corino Therapeutics Company Details

Table 69. Corino Therapeutics Business Overview

Table 70. Corino Therapeutics Familial Amyloid Polyneuropathy Product

Table 71. Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2020-2025) & (US$ Million)

Table 72. Corino Therapeutics Recent Development

Table 73. Proclara Bioscience Company Details

Table 74. Proclara Bioscience Business Overview

Table 75. Proclara Bioscience Familial Amyloid Polyneuropathy Product

Table 76. Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2020-2025) & (US$ Million)

Table 77. Proclara Bioscience Recent Development

Table 78. Arcturus Therapeutics Company Details

Table 79. Arcturus Therapeutics Business Overview

Table 80. Arcturus Therapeutics Familial Amyloid Polyneuropathy Product

Table 81. Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2020-2025) & (US$ Million)

Table 82. Arcturus Therapeutics Recent Development

Table 83. Research Programs/Design for This Report

Table 84. Key Data Information from Secondary Sources

Table 85. Key Data Information from Primary Sources

Table 86. Authors List of This Report

List of Figures

Figure 1. Familial Amyloid Polyneuropathy Picture

Figure 2. Global Familial Amyloid Polyneuropathy Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Familial Amyloid Polyneuropathy Market Share by Type: 2024 VS 2031

Figure 4. FAP-I Features

Figure 5. FAP-II Features

Figure 6. FAP-III Features

Figure 7. FAP-IV Features

Figure 8. Global Familial Amyloid Polyneuropathy Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Familial Amyloid Polyneuropathy Market Share by Application: 2024 VS 2031

Figure 10. Hospitals and Clinics Case Studies

Figure 11. Others Case Studies

Figure 12. Familial Amyloid Polyneuropathy Report Years Considered

Figure 13. Global Familial Amyloid Polyneuropathy Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Familial Amyloid Polyneuropathy Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Familial Amyloid Polyneuropathy Market Share by Region: 2024 VS 2031

Figure 16. Global Familial Amyloid Polyneuropathy Market Share by Players in 2024

Figure 17. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Revenue in 2024

Figure 19. North America Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Familial Amyloid Polyneuropathy Market Share by Country (2020-2031)

Figure 21. United States Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Familial Amyloid Polyneuropathy Market Share by Country (2020-2031)

Figure 25. Germany Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Familial Amyloid Polyneuropathy Market Share by Region (2020-2031)

Figure 33. China Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Familial Amyloid Polyneuropathy Market Share by Country (2020-2031)

Figure 41. Mexico Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Familial Amyloid Polyneuropathy Market Share by Country (2020-2031)

Figure 45. Turkey Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Familial Amyloid Polyneuropathy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Pfizer Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2020-2025)

Figure 49. GSK Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2020-2025)

Figure 50. Ionis Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2020-2025)

Figure 51. Alnylam Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2020-2025)

Figure 52. Corino Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2020-2025)

Figure 53. Proclara Bioscience Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2020-2025)

Figure 54. Arcturus Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2020-2025)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions